Sit Investment Associates Inc. Decreases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sit Investment Associates Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,547 shares of the medical research company's stock after selling 1,933 shares during the quarter. Sit Investment Associates Inc.'s holdings in Thermo Fisher Scientific were worth $12,770,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grantham Mayo Van Otterloo & Co. LLC raised its holdings in Thermo Fisher Scientific by 140.7% in the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after purchasing an additional 639,467 shares during the period. Dynamic Technology Lab Private Ltd boosted its stake in Thermo Fisher Scientific by 68.6% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 2,180 shares of the medical research company's stock worth $1,134,000 after buying an additional 887 shares during the period. Mizuho Bank Ltd. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth about $57,000. Resona Asset Management Co. Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $57,107,000. Finally, Riverwater Partners LLC increased its position in shares of Thermo Fisher Scientific by 5.3% in the 4th quarter. Riverwater Partners LLC now owns 1,812 shares of the medical research company's stock valued at $943,000 after purchasing an additional 91 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 in the last three months. Corporate insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Raymond James reiterated an "outperform" rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday. Scotiabank upped their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Finally, StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $647.09.

Thermo Fisher Scientific Trading Down 6.3 %

Shares of Thermo Fisher Scientific stock traded down $28.70 during midday trading on Thursday, reaching $424.85. The company had a trading volume of 1,896,501 shares, compared to its average volume of 1,682,377. The firm has a market cap of $160.28 billion, a PE ratio of 25.74, a P/E/G ratio of 2.99 and a beta of 0.86. The stock has a fifty day moving average price of $516.75 and a 200 day moving average price of $541.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.